



MYND Life Sciences announces funding for Psilocybin research on Neuroinflammation

R&D project on psilocybin's benefits in treating diseases of the brain

VANCOUVER, BRITISH COLUMBIA, November 30, 2021 – **MYND Life Sciences Inc.** (“**MYND**” or the “**Company**”) (**CSE:MYND**) (**OTC:MYNDF**) is pleased and extremely grateful to acknowledge the financial contribution from the Government of Canada towards an important component of its research and development into the positive effects of psilocybin on treating diseases of the brain.

MYND Life Sciences will benefit from advisory services and up to \$45,600 in funding from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) to support a prescribed research and development project that will run from November 2021 to March 2022.

“We are very pleased for the support from the Government of Canada, both from the business advisory perspective, as well as the valued funding support,” said Dr. Lyle Oberg, MD, CEO, MYND Life Sciences. “We are taking a broad-based, measured approach to harness private capital investment, invaluable university research infrastructure, and guidance backed with funding from important government research enablers to tackle some of the most serious diseases of the brain and central nervous system.”

The project is titled *Phytochemical-analog(s) as a novel method for management of treatment resistant depression*. The objective of the research and development is to determine how psilocybin analogs target a particular gene pathway to modulate brain function.

“This support through NRC IRAP is well timed and will enable an important piece of our overall approach to creating novel innovations to improve the lives of people suffering from diseases of the Central Nervous System,” stated Dr. Wilfred Jefferies, Chief Science Officer, MYND Life Sciences.

ABOUT MYND LIFE SCIENCES INC.

MYND Life Sciences Inc. is a medical biotech drug research and development company focused on neuro-pharmaceutical and novel psilocybin drug development, diagnostics and vaccines. The Company is advancing pharmaceuticals through rigorous science and clinical trials, while diligently patenting and safeguarding its intellectual property. For more information and to subscribe to MYND’s mailing list, please visit <https://myndsciences.com/contact/>.

CONTACT INFORMATION

Dr. Lyle Oberg, MD, CEO

Email: ir@myndsciences.com

Web: www.myndsciences.com

Forward-Looking Statements

This news release contains forward-looking statements and information within the meaning of applicable securities legislation. Often, but not always, forward-looking statements and information can be identified by the use of words such as "plans", "expects" or "does not expect", "is expected", "estimates", "intends", "anticipates" or "does not anticipate", or "believes", or variations of such words and phrases or state that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved. Forward-looking statements or information involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of MYND to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements or information contained in this release.

Risks, uncertainties and other factors involved with forward-looking information could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information. The Canadian Securities Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release.

None of the securities issued in connection with the Offering will be registered under the United States Securities Act of 1933, as amended (the "1933 Act"), and none of them may be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the 1933 Act. This press release shall not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of the securities in any state where such offer, solicitation, or sale would be unlawful.